See the published version of this preprint at Diabetology & Metabolic Syndrome.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Wanwan Luo
Taizhou First People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-6424-021X
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.
Methods: Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case-control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese.
Results: Twenty-five studies involving 2498 DM patients and 1424 healthy controls were included. Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD=1.62, 95%CI, 1.08 to 2.25, P=0.000; GDM: SMD=2.85, 95%CI, 1.01 to 4.70, P=0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD=1.58, 95%CI, 0.59 to 2.56, P=0.002; microalbuminuria: SMD=2.57, 95%CI, 0.92 to 4.22, P=0.002; macroalbuminuria: SMD=2.69, 95%CI, 1.40 to 3.98, P=0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD=1.49, 95%CI, 0.28 to 2.71, P=0.016; macroalbuminuria vs microalbuminuria: SMD=0.93, 95%CI, 0.34 to 1.52, P=0.002).
Conclusions: DM patients have higher levels of YKL-40 compared with healthy controls. Additionally, levels of YKL-40 are significantly higher in DM patients with different degree of albuminuria than in the healthy controls and the levels of YKL-40 are positively related with the severe degree of albuminuria. Therefore, our current meta-analysis suggests that their sera should be detected for YKL-40, if DM, especially DN, is suspected in patients.
Keywords
diabetes mellitus, YKL-40, diabetic nephropathy, meta-analysis
Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Diabetology & Metabolic Syndrome.
No community comments so far
Editorial decision: Accept
On 04 Jan, 2021
Review #2 received
Received 03 Jan, 2021
Review #1 received
Received 30 Dec, 2020
Reviewer #2 agreed
On 25 Dec, 2020
Editor assigned
On 22 Dec, 2020
Reviewers invited
Invitations sent on 22 Dec, 2020
Reviewer #1 agreed
On 22 Dec, 2020
Submission checks complete
On 22 Dec, 2020
Editor invited
On 22 Dec, 2020
Version 2
Posted 19 Nov, 2020
No comments provided
Editorial decision: Major revision
On 25 Nov, 2020
Review #2 received
Received 24 Nov, 2020
Reviewer #2 agreed
On 21 Nov, 2020
Reviewer #1 agreed
On 17 Nov, 2020
Review #1 received
Received 17 Nov, 2020
Reviewers invited
Invitations sent on 17 Nov, 2020
Editor assigned
On 16 Nov, 2020
Submission checks complete
On 16 Nov, 2020
Editor invited
On 16 Nov, 2020
No comments provided
Editorial decision: Minor revision
On 22 Oct, 2020
Review #2 received
Received 21 Oct, 2020
Reviewer #2 agreed
On 08 Oct, 2020
Review #1 received
Received 14 Sep, 2020
Reviewer #1 agreed
On 12 Sep, 2020
Editor assigned
On 26 Aug, 2020
Reviewers invited
Invitations sent on 26 Aug, 2020
First submitted
On 26 Aug, 2020
Submission checks complete
On 25 Aug, 2020
Editor invited
On 25 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Endocrinology & Metabolism
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Diabetology & Metabolic Syndrome.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Wanwan Luo
Taizhou First People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-6424-021X
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Diabetology & Metabolic Syndrome.
No community comments so far
Editorial decision: Accept
On 04 Jan, 2021
Review #2 received
Received 03 Jan, 2021
Review #1 received
Received 30 Dec, 2020
Reviewer #2 agreed
On 25 Dec, 2020
Editor assigned
On 22 Dec, 2020
Reviewers invited
Invitations sent on 22 Dec, 2020
Reviewer #1 agreed
On 22 Dec, 2020
Submission checks complete
On 22 Dec, 2020
Editor invited
On 22 Dec, 2020
Version 2
Posted 19 Nov, 2020
No comments provided
Editorial decision: Major revision
On 25 Nov, 2020
Review #2 received
Received 24 Nov, 2020
Reviewer #2 agreed
On 21 Nov, 2020
Reviewer #1 agreed
On 17 Nov, 2020
Review #1 received
Received 17 Nov, 2020
Reviewers invited
Invitations sent on 17 Nov, 2020
Editor assigned
On 16 Nov, 2020
Submission checks complete
On 16 Nov, 2020
Editor invited
On 16 Nov, 2020
No comments provided
Editorial decision: Minor revision
On 22 Oct, 2020
Review #2 received
Received 21 Oct, 2020
Reviewer #2 agreed
On 08 Oct, 2020
Review #1 received
Received 14 Sep, 2020
Reviewer #1 agreed
On 12 Sep, 2020
Editor assigned
On 26 Aug, 2020
Reviewers invited
Invitations sent on 26 Aug, 2020
First submitted
On 26 Aug, 2020
Submission checks complete
On 25 Aug, 2020
Editor invited
On 25 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Endocrinology & Metabolism
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Diabetology & Metabolic Syndrome.
Background: Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.
Methods: Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case-control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese.
Results: Twenty-five studies involving 2498 DM patients and 1424 healthy controls were included. Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD=1.62, 95%CI, 1.08 to 2.25, P=0.000; GDM: SMD=2.85, 95%CI, 1.01 to 4.70, P=0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD=1.58, 95%CI, 0.59 to 2.56, P=0.002; microalbuminuria: SMD=2.57, 95%CI, 0.92 to 4.22, P=0.002; macroalbuminuria: SMD=2.69, 95%CI, 1.40 to 3.98, P=0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD=1.49, 95%CI, 0.28 to 2.71, P=0.016; macroalbuminuria vs microalbuminuria: SMD=0.93, 95%CI, 0.34 to 1.52, P=0.002).
Conclusions: DM patients have higher levels of YKL-40 compared with healthy controls. Additionally, levels of YKL-40 are significantly higher in DM patients with different degree of albuminuria than in the healthy controls and the levels of YKL-40 are positively related with the severe degree of albuminuria. Therefore, our current meta-analysis suggests that their sera should be detected for YKL-40, if DM, especially DN, is suspected in patients.
Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Loading...